Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Xingshun New Material Co., Ltd. is a leading Chinese chemical manufacturer specializing in fine chemicals and pharmaceutical intermediates. Founded in 1996 as Changzhou Wujin Linchuan Chemical, the company established its primary production base in Shandong in 2018 and operates its sales and R&D headquarters under the name Changzhou Xingsheng Technology. The company is a dominant global producer of 1-chloromethyl naphthalene and chloromethyl styrene (VBC) derivatives, which are critical building blocks for high-performance polymers, electronic chemicals, and pharmaceutical synthesis. Its products support the manufacturing of various life science applications, including intermediates for antifungal medications like Terbinafine. Shandong Xingshun maintains ISO-certified facilities in Shandong and Jiangsu provinces and serves a global market including the United States, Europe, and East Asia. The company is recognized for its strong R&D capabilities and large-scale production capacity, positioning it as a key supplier in the global specialty chemicals supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Xingshun New Material.